CHDI Foundation

9 April 2019

Charles River Laboratories and CHDI Foundation extend Huntington’s disease collaboration

WILMINGTON, Mass. – April 9, 2019 — Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation today announced a five-year extension of their ongoing collaboration. The organizations began working together in 2005 on drug discovery and development for Huntington’s disease (HD), a genetic neurological disease that causes the progressive dysfunction of nerve cells in the brain. The extension will allow more flexible activity across the different Charles River platforms and entail greater integration into CHDI’s programs. Read more…

19 December 2018

New Enroll-HD clinical dataset now available

December 18, 2018 – A new data cut from the Enroll-HD observational study, named periodic dataset 4 (PDS4), was made available for download to any interested researcher on December 14, 2018. PDS4 comprises data from 15,301 participants, representing approximately 80% of the total number of participants. The PDS4 file structure is the same as the previous dataset, PDS3 Plus, and contains additional longitudinal data from 3,802 Enroll-HD participants who also took part in the REGISTRY study. There is also clinical data for some participants collected in ad hoc visits prior to their Enroll-HD/REGISTRY study participation. As a guide to the longitudinal nature of PDS4, participants who are only taking part in Enroll-HD have up to 6 visits, those in Enroll-HD plus REGISTRY have up to 20 visits, and those who were part of Enroll-HD and REGISTRY plus ad hoc data have up to 32 visits. Read more…